Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease

ClinicalTrials.gov ID: NCT02927184

Public ClinicalTrials.gov record NCT02927184. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 12:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess The Efficacy, Safety, and Tolerability of VK2809 Administered for 12 Weeks Followed by a 4-Week Off-Drug Phase in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will investigate the efficacy, safety, and tolerability of VK2809 in lowering LDL-C and liver fat content in patients with primary hypercholesterolemia and fatty liver disease. The primary efficacy endpoint is percent change from baseline LDL-C at the end of the treatment period (Week 12). Secondary endpoints include effects on liver fat content and other liver and lipid markers, as well as effects on safety and tolerability, and pharmacokinetic (PK) measurements.

Study identification

NCT ID
NCT02927184
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Viking Therapeutics, Inc.
Industry
Enrollment
59 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 27, 2016
Primary completion
Mar 25, 2019
Completion
Mar 25, 2019
Last update posted
Apr 25, 2021

2016 – 2019

United States locations

U.S. sites
19
U.S. states
10
U.S. cities
16
Facility City State ZIP Site status
Radiant Research, Inc. Chandler Arizona 85224
SC Clinical Research Garden Grove California 92844
ACTCA Los Angeles California
Catalina Research Institute Montclair California 91763
North America Research, Inc Pomona California 91767
Orange County Research Center Tustin California 92780
Research Institute of South Florida Miami Florida 33173
Research Institute of South Florida Miami Florida
Avant Research Associates, LLC Crowley Louisiana 70526
HCI- MetroMedic Walk-in New Bedford Massachusetts 02740
HCI- MetroMedic Walk-in New Bedford Massachusetts
Flint Clinical Research, PLLC Flint Michigan 48503
Mid Hudson Medical Hopewell Junction New York 12533
CHEAR Center, LLC The Bronx New York 10459
Wake Research Associcates, LLC. Raleigh North Carolina 27612
Avant Research Beaumont Texas 77702
Clinical Trials of Texas, INC San Antonio Texas 78229
Radiant Research, Inc. San Antonio Texas 78229
Wasatch Clinical Research, LLC Salt Lake City Utah 84107

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02927184, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 25, 2021 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02927184 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →